Drug Pricing: US Senate Hearings Conclude With No Clear View On Legislation
Measures that would increase financial transparency and empower federal government to negotiate drug prices highlighted by National Academies representative who discussed recent report on drug affordability, but former Congressional Budget Office Director Holtz-Eakin warns Senate HELP Committee against taking measures that merely shift costs from one party to another.
You may also be interested in...
There was little on specific legislative proposals and a lot of time discussing broad questions that Congress has been asking for years about drug pricing.
State of the Union address touts FDA's record number of approvals, but also endorses right to try proposals and renews president's call for lower drug prices.
Energy & Commerce Health Subcommittee hearing on drug pricing and the supply chain begins information gathering process, leadership says. Subcommittee Chair Burgess urges stakeholders to seek consensus on market-based solutions – or else.